Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F13DK
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,268
Award facts
- Contract value 100% obligated
- $9,267.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,267.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit dose packages) on December 1, 2025, with completion scheduled for December 2, 2025. This competitively awarded, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal medical procurement needs.
AmerisourceBergen Drug Corp serves as a critical supplier of pharmaceuticals and medical supplies across the Defense Health Agency's supply chain, delivering medications spanning multiple therapeutic domains to support military healthcare systems worldwide. RINVOQ (upadacitinib) is a JAK inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of specialty medications that AmerisourceBergen provides under its DLA contracts. As a major healthcare solutions provider registered in SAM.gov, the company regularly fulfills federal procurement requirements through open competition, with this delivery order representing one of numerous small-to-medium value pharmaceutical transactions supporting military medical operations.
Quick answers
Who was awarded contract SPE2DR26F13DK?
SPE2DR26F13DK was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26F13DK worth?
The government has obligated $9,268 on SPE2DR26F13DK.
Is contract SPE2DR26F13DK an order under another contract?
Yes. SPE2DR26F13DK is a delivery order under SPE2DR25D1110, an indefinite delivery contract.
Was contract SPE2DR26F13DK competed?
The extent of competition for SPE2DR26F13DK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award